In the face of looming revenue decline from blood cancer medication Revlimid, Indian pharma companies Natco Pharma and Dr.
Fund Of The Week quizzes fund managers about how they’re investing your money. If you’d like to suggest which funds you want ...
There's a boom in the use of weight loss medications with more new ones on their way, but they are recommended only for the clinically obese. A slew of new weight loss drugs are being tested in 2025.
The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...
Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...
These three stocks just announced significant quarterly dividend increases that they are set to pay out soon. While they all ...
Where could be the top place to invest this spring? Europe. That's according to the latest edition of the hugely influential ...
A 52-year-old man has knocked his decade-long cocaine addiction on the head after receiving weight-loss injections. The jab ...
There are many opportunities available in the international markets that never make the news in the US. The VEA and VWO ETFs ...
As the demand for GLP-1 weight loss medications such as Ozempic, Wegovy, and Zepbound continues to skyrocket, new survey ...
Zacks Small Cap Research on MSN18h
RANI: Impressive Bioavailability for RT-116
RANI READ THE FULL RANI RESEARCH REPORT On February 5 th , Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of ...